IBDEI0AO ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5025,1,4,0)
 ;;=4^249.40
 ;;^UTILITY(U,$J,358.3,5025,1,5,0)
 ;;=5^Secondary DM w/ Renal Complications
 ;;^UTILITY(U,$J,358.3,5025,2)
 ;;=^336732
 ;;^UTILITY(U,$J,358.3,5026,0)
 ;;=249.60^^41^479^47
 ;;^UTILITY(U,$J,358.3,5026,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5026,1,4,0)
 ;;=4^249.60
 ;;^UTILITY(U,$J,358.3,5026,1,5,0)
 ;;=5^Secondary DM w/ Neuro Complications
 ;;^UTILITY(U,$J,358.3,5026,2)
 ;;=^336734
 ;;^UTILITY(U,$J,358.3,5027,0)
 ;;=257.2^^41^479^31
 ;;^UTILITY(U,$J,358.3,5027,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5027,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,5027,1,5,0)
 ;;=5^Hypogonadism
 ;;^UTILITY(U,$J,358.3,5027,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,5028,0)
 ;;=255.42^^41^479^38
 ;;^UTILITY(U,$J,358.3,5028,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5028,1,4,0)
 ;;=4^255.42
 ;;^UTILITY(U,$J,358.3,5028,1,5,0)
 ;;=5^Mineralcorticoid Deficient
 ;;^UTILITY(U,$J,358.3,5028,2)
 ;;=^335241
 ;;^UTILITY(U,$J,358.3,5029,0)
 ;;=259.50^^41^479^2
 ;;^UTILITY(U,$J,358.3,5029,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5029,1,4,0)
 ;;=4^259.50
 ;;^UTILITY(U,$J,358.3,5029,1,5,0)
 ;;=5^Androgen Insensitivity,Unspec
 ;;^UTILITY(U,$J,358.3,5029,2)
 ;;=^336738
 ;;^UTILITY(U,$J,358.3,5030,0)
 ;;=275.5^^41^479^18
 ;;^UTILITY(U,$J,358.3,5030,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5030,1,4,0)
 ;;=4^275.5
 ;;^UTILITY(U,$J,358.3,5030,1,5,0)
 ;;=5^Hungry Bone Syndrome
 ;;^UTILITY(U,$J,358.3,5030,2)
 ;;=^336538
 ;;^UTILITY(U,$J,358.3,5031,0)
 ;;=793.2^^41^480^3
 ;;^UTILITY(U,$J,358.3,5031,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5031,1,4,0)
 ;;=4^793.2
 ;;^UTILITY(U,$J,358.3,5031,1,5,0)
 ;;=5^Abnormal Chest x-ray, other
 ;;^UTILITY(U,$J,358.3,5031,2)
 ;;=^273419
 ;;^UTILITY(U,$J,358.3,5032,0)
 ;;=277.6^^41^480^5
 ;;^UTILITY(U,$J,358.3,5032,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5032,1,4,0)
 ;;=4^277.6
 ;;^UTILITY(U,$J,358.3,5032,1,5,0)
 ;;=5^Alpha-1 antitrypsin deficiency
 ;;^UTILITY(U,$J,358.3,5032,2)
 ;;=^87463
 ;;^UTILITY(U,$J,358.3,5033,0)
 ;;=493.92^^41^480^6
 ;;^UTILITY(U,$J,358.3,5033,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5033,1,4,0)
 ;;=4^493.92
 ;;^UTILITY(U,$J,358.3,5033,1,5,0)
 ;;=5^Asthma, Acute Exacerbation
 ;;^UTILITY(U,$J,358.3,5033,2)
 ;;=^322001
 ;;^UTILITY(U,$J,358.3,5034,0)
 ;;=493.20^^41^480^11
 ;;^UTILITY(U,$J,358.3,5034,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5034,1,4,0)
 ;;=4^493.20
 ;;^UTILITY(U,$J,358.3,5034,1,5,0)
 ;;=5^COPD with Asthma
 ;;^UTILITY(U,$J,358.3,5034,2)
 ;;=COPD with Asthma^269964
 ;;^UTILITY(U,$J,358.3,5035,0)
 ;;=493.91^^41^480^7
 ;;^UTILITY(U,$J,358.3,5035,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5035,1,4,0)
 ;;=4^493.91
 ;;^UTILITY(U,$J,358.3,5035,1,5,0)
 ;;=5^Asthma, with Status Asthmat
 ;;^UTILITY(U,$J,358.3,5035,2)
 ;;=^269967
 ;;^UTILITY(U,$J,358.3,5036,0)
 ;;=491.21^^41^480^10
 ;;^UTILITY(U,$J,358.3,5036,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5036,1,4,0)
 ;;=4^491.21
 ;;^UTILITY(U,$J,358.3,5036,1,5,0)
 ;;=5^COPD Exacerbation
 ;;^UTILITY(U,$J,358.3,5036,2)
 ;;=COPD Exacerbation^269954
 ;;^UTILITY(U,$J,358.3,5037,0)
 ;;=494.0^^41^480^9
 ;;^UTILITY(U,$J,358.3,5037,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5037,1,4,0)
 ;;=4^494.0
 ;;^UTILITY(U,$J,358.3,5037,1,5,0)
 ;;=5^Bronchiectasis, chronic
 ;;^UTILITY(U,$J,358.3,5037,2)
 ;;=^321990
 ;;^UTILITY(U,$J,358.3,5038,0)
 ;;=494.1^^41^480^8
 ;;^UTILITY(U,$J,358.3,5038,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5038,1,4,0)
 ;;=4^494.1
 ;;^UTILITY(U,$J,358.3,5038,1,5,0)
 ;;=5^Bronchiectasis with exacerb
 ;;^UTILITY(U,$J,358.3,5038,2)
 ;;=^321991
